



Outlook Therapeutics Announces Addition of Jennifer M. Kissner, Ph.D. as Senior Vice President, Clinical Development

April 26, 2019

CRANBURY, N.J., April 26, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the "Company"), a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina diseases, today announced that Jennifer M. Kissner, Ph.D. has joined the Company as Senior Vice President, Clinical Development.

Dr. Kissner has extensive experience in therapeutic product development from the benchtop through clinical development and regulatory filing, including small molecules, biologics, gene therapy and devices, across multiple therapeutic areas, specifically working in the retina space for 12 years. She also brings global experience leading development programs across the US, EU and Asia Pacific regions. Most recently, Dr. Kissner was Vice President, Clinical Development at Clearside Biomedical where she led global clinical development for a platform technology. Previously, she was Director, Clinical Development at Acucela and held increasing roles of responsibility in Retina Development at Alcon.

"We would like to extend a warm welcome to Jennifer and are excited that she has joined the Outlook team," said Terry Dagnon, Chief Operating Officer at Outlook Therapeutics. "Dr. Kissner's extensive clinical development expertise, specializing in wet AMD and other retina diseases, will be an important asset to Outlook Therapeutics as we continue to advance the ONS-5010 program."

Separately, Kenneth M. Bahr, M.D., the Company's Chief Medical Officer, has announced his departure from Outlook Therapeutics to pursue other opportunities. The Company does not intend to hire a new Chief Medical Officer at this time and will rely on Dr. Kissner and existing contracted services from MTTR, LLC to oversee ongoing clinical activities for ONS-5010.

"On behalf of the entire Outlook team, I would like to thank Dr. Bahr for his valuable contributions to the Company for the past four years and wish him the best in his future endeavors," said Lawrence Kenyon, President, Chief Executive Officer, and Chief Financial Officer of Outlook Therapeutics. "These organizational changes reflect the continued evolution of Outlook Therapeutics as part of our strategy to focus on retinal diseases and we believe that we have the key people in place to successfully advance the ONS-5010 program. Our plans to submit ONS-5010 for regulatory approval in multiple markets in 2020 have not changed."

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina diseases. ONS-5010 is currently in Phase 3 clinical trials for patients suffering from wet AMD. For more information, please visit www.outlooktherapeutics.com.

Forward Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are "forward-looking statements," including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as "will," "plan," "continue," "may," "might," "should," "expect," "anticipate," "project," "believe," "estimate," "predict," "potential," and "intend" or the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include statements about the Company's expectations for Dr. Kissner, its ongoing ONS-5010 development program, its ability to advance ONS-5010 and plans for seeking regulatory approval for ONS-5010, including timing thereof. Although the Company believes that it has a reasonable basis for forward-looking statements contained herein, they are based on current expectations about future events affecting the Company and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing pharmaceutical product candidates, risks of conducting clinical trials, and risks in obtaining necessary regulatory approvals, as well as those risks detailed in the Company's annual report on Form 10-K for the year ended September 30, 2018 and in its other filings with the Securities and Exchange Commission. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

CONTACTS:

Outlook Therapeutics:

Lawrence A. Kenyon

LawrenceKenyon@outlooktherapeutics.com

Media & Investors:

Jeremy Feffer

Managing Director

LifeSci Advisors, LLC

T: 212.915.2568

jeremy@lifesciadvisors.com



Source: Outlook Therapeutics, Inc.